Preferred test for individuals with idiopathic pancreatitis who are <20 years of age or have two affected first-degree relatives.
Polymerase Chain Reaction/Sequencing and Multiplex Ligation Dependent Probe Amplification
Lavender (K2EDTA), Pink (K2EDTA), or Yellow (ACD Solution A or B).
Transport 3 mL whole blood. (Min: 2 mL)
Ambient: 1 week; Refrigerated: 1 month; Frozen: 6 months
Background Information for Pancreatitis (PRSS1) Sequencing and Deletion/Duplication
Characteristics: Characteristics of PRSS1-related hereditary pancreatitis: Recurrent episodes of pancreatic inflammation that typically begin to present in late childhood, often with signs and symptoms including abdominal pain, nausea, and vomiting. Ultimately, these recurrent episodes of acute pancreatitis progress to permanent damage of the pancreas.
Epidemiology: Incidence of chronic pancreatitis: 5-12 in 100,000 per year
Prevalence of chronic pancreatitis: approximately 50 in 100,000
Inheritance: Autosomal dominant.
Penetrance: Varies geographically; estimated at 80 percent in the US.
Cause: Pathogenic variants in the cationic trypsinogen (PRSS1) gene.
Clinical Sensitivity: 15 percent of hereditary pancreatitis is caused by pathogenic PRSS1 copy number variants or sequence variants.
Methodology: Bidirectional sequencing of PRSS1 coding regions and intron/exon boundaries and multiplex ligation-dependent probe amplification (MLPA) of the PRSS1 gene.
Analytical Sensitivity and Specificity: 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations. Regulatory region variants and deep intronic variants will not be detected. The breakpoints of large deletions/duplications will not be determined. Variants in genes other than PRSS1 are not evaluated.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online at www.aruplab.com
Compliance Statement C: For human genetic inheritable conditions and mutations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
|Component Test Code*||Component Chart Name||LOINC|
|3001769||PRSS1 FGA Spcm||31208-2|
|3001770||PRSS1 FGA Interp||21692-9|
- hereditary pancreatitis
- Idiopathic pancreatitis molecular sequencing
- PANC PANEL